TARGETED PROTEIN DEGRADATION WITH PROTACS IN CANCER THERAPY: MECHANISMS, CLINICAL ADVANCES, CHALLENGES, AND FUTURE PERSPECTIVES
International Journal of Advanced Research · 31.07.2026 · 14 (07) · 919-942
DOI: 10.21474/ijar01/23847 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Advanced Research, online erschienen am 31.07.2026. Verfasst von N. Vijaya Lakshmi Reddy und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Targeted protein degradation (TPD) has emerged as one of the most transformational approaches in current drug development, fundamentally challenging the long-standing assumption that small compounds must only inhibit their protein targets. Among TPD methods, proteolysis-targeting chimeras (PROTACs) have attracted considerable attention from both academic researchers and clinicians, giving a catalytic mechanism that permits the total removal of disease-driving proteins rather than just reducing their activity. This thorough analysis investigates the molecular basis of PROTAC technology, tracking its progression from an elegant intellectual notion to a clinically approved treatment platform. We discuss the molecular machinery of the ubiquitin - proteas ome system that PROTACs exploit, analyze the structural design principles underlying effective degrader molecules, and provide a detailed survey of the current clinical landscape,including the landmark progression of vepdegestrant (ARV-471) through Phase III clinical evaluation, culminating in U.S. Food and Drug Administration (FDA) approval on May 1, 2026.
Zitieren
APA
Reddy, N. V. L., Sarika, M., Deepika, V., Bindu, M. H., & Hussain, S. A. (2026). TARGETED PROTEIN DEGRADATION WITH PROTACS IN CANCER THERAPY: MECHANISMS, CLINICAL ADVANCES, CHALLENGES, AND FUTURE PERSPECTIVES. International Journal of Advanced Research, 14(07), 919-942. https://doi.org/10.21474/ijar01/23847
Vancouver
Reddy NVL, Sarika M, Deepika V, Bindu MH, Hussain SA. TARGETED PROTEIN DEGRADATION WITH PROTACS IN CANCER THERAPY: MECHANISMS, CLINICAL ADVANCES, CHALLENGES, AND FUTURE PERSPECTIVES. International Journal of Advanced Research. 2026;14(07):919-942. doi:10.21474/ijar01/23847
BibTeX
@article{Reddy2026,
author = {Reddy, N. Vijaya Lakshmi and Sarika, M. and Deepika, V. and Bindu, M. Hima and Hussain, Syed Ahad},
title = {TARGETED PROTEIN DEGRADATION WITH PROTACS IN CANCER THERAPY: MECHANISMS, CLINICAL ADVANCES, CHALLENGES, AND FUTURE PERSPECTIVES},
journal = {International Journal of Advanced Research},
year = {2026},
volume = {14},
number = {07},
pages = {919--942},
doi = {10.21474/ijar01/23847}
}
EUVIMED